china sxt pharmaceuticals inc - SXTC

SXTC

Close Chg Chg %
1.60 0.19 11.88%

Closed Market

1.79

+0.19 (11.88%)

Volume: 203.07K

Last Updated:

Jan 2, 2026, 4:00 PM EDT

Company Overview: china sxt pharmaceuticals inc - SXTC

SXTC Key Data

Open

$1.61

Day Range

1.61 - 1.79

52 Week Range

0.95 - 7.84

Market Cap

$185.64M

Shares Outstanding

116.03M

Public Float

75.04M

Beta

1.40

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

$120.64

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

73.12K

 

SXTC Performance

1 Week
 
15.28%
 
1 Month
 
23.45%
 
3 Months
 
6.14%
 
1 Year
 
-58.08%
 
5 Years
 
-99.97%
 

SXTC Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings
Full Ratings ➔

About china sxt pharmaceuticals inc - SXTC

China Sxt Pharmaceuticals, Inc. operates as a holding company, which engages in the research, development, manufacture, marketing, and sales of traditional Chinese medicine pieces (TCMP). Its product categories include directly-oral, after-soaking-oral, fine, and regular TCMP. The firm distributes its product under the Suxuantang brand. The company was founded by Feng Zhou in 2005 and is headquartered in Taizhou, China.

SXTC At a Glance

China Sxt Pharmaceuticals, Inc.
178 Taidong North Road
Taizhou, Jiangsu 225300
Phone 86-523-86299087 Revenue 1.74M
Industry Pharmaceuticals: Major Net Income -3,303,652.00
Sector Health Technology Employees 75
Fiscal Year-end 03 / 2026
View SEC Filings

SXTC Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 2.04
Price to Book Ratio 2.224
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA 8.539
Enterprise Value to Sales -7.809
Total Debt to Enterprise Value -0.072

SXTC Efficiency

Revenue/Employee 23,212.093
Income Per Employee -44,048.693
Receivables Turnover 1.338
Total Asset Turnover 0.078

SXTC Liquidity

Current Ratio 3.542
Quick Ratio 3.354
Cash Ratio 3.016

SXTC Profitability

Gross Margin 21.105
Operating Margin -96.181
Pretax Margin -189.766
Net Margin -189.766
Return on Assets -14.752
Return on Equity -22.497
Return on Total Capital -20.115
Return on Invested Capital -22.115

SXTC Capital Structure

Total Debt to Total Equity 6.372
Total Debt to Total Capital 5.991
Total Debt to Total Assets 4.542
Long-Term Debt to Equity 1.371
Long-Term Debt to Total Capital 1.289
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for China Sxt Pharmaceuticals Inc - SXTC

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
2.60M 1.97M 1.93M 1.74M
Sales Growth
-45.53% -24.23% -2.19% -9.73%
Cost of Goods Sold (COGS) incl D&A
1.35M 1.55M 1.37M 1.37M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
320.01K 250.16K 203.25K 82.30K
Depreciation
311.54K 242.23K 195.79K 75.06K
Amortization of Intangibles
8.47K 7.93K 7.46K 7.24K
COGS Growth
-30.31% +14.42% -11.06% -0.08%
Gross Income
1.25M 426.27K 553.97K 367.43K
Gross Income Growth
-55.92% -65.94% +29.96% -33.67%
Gross Profit Margin
+48.10% +21.62% +28.73% +21.11%
2022 2023 2024 2025 5-year trend
SG&A Expense
6.44M 6.03M 2.65M 2.04M
Research & Development
- - 184.19K 191.39K
-
Other SG&A
6.44M 6.03M 2.46M 1.85M
SGA Growth
+41.01% -6.33% -56.14% -22.84%
Other Operating Expense
- - - -
-
Unusual Expense
- - 422.92K 1.01M
-
EBIT after Unusual Expense
(5.19M) (5.61M) (2.52M) (2.68M)
Non Operating Income/Expense
(181.58K) 149.51K (39.04K) 25.05K
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
36.70K 476.78K 544.28K 648.22K
Interest Expense Growth
-97.73% +1,199.29% +14.16% +19.10%
Gross Interest Expense
36.70K 476.78K 544.28K 648.22K
Interest Capitalized
- - - -
-
Pretax Income
(5.41M) (5.93M) (3.10M) (3.30M)
Pretax Income Growth
-83.89% -9.74% +47.79% -6.62%
Pretax Margin
-207.82% -301.00% -160.67% -189.77%
Income Tax
- - - 328.15K
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - 328.15K
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(5.74M) (5.93M) (3.10M) (3.30M)
Minority Interest Expense
- - - -
-
Net Income
(5.74M) (5.93M) (3.10M) (3.30M)
Net Income Growth
-108.72% -3.46% +47.79% -6.62%
Net Margin Growth
-220.43% -301.00% -160.67% -189.77%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(5.74M) (5.93M) (3.10M) (3.30M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(5.74M) (5.93M) (3.10M) (3.30M)
EPS (Basic)
-22066.88 -177.838 -28.577 -2.3211
EPS (Basic) Growth
-2,788.79% +99.19% +83.93% +91.88%
Basic Shares Outstanding
259.94149999999996 33.37K 108.43K 1.42M
EPS (Diluted)
-22066.88 -177.838 -28.577 -2.3211
EPS (Diluted) Growth
-2,788.79% +99.19% +83.93% +91.88%
Diluted Shares Outstanding
259.94149999999996 33.37K 108.43K 1.42M
EBITDA
(4.87M) (5.36M) (1.89M) (1.59M)
EBITDA Growth
-252.11% -10.01% +64.74% +15.72%
EBITDA Margin
-187.13% -271.72% -97.95% -91.45%

China Sxt Pharmaceuticals Inc in the News